Harpoon Therapeutics introduced Haibo Wang as its SVP of small business development this 7 days.
Wang, who joins Harpoon from Hummingbird Bioscience, has a qualifications of 15 a long time in biopharma business enterprise enhancement and finance, as properly as mergers and acquisitions.
At Hummingbird, Wang was VP of organization advancement. Prior to that, he served as director of organization progress at Amgen and served facilitate the company’s acquisitions of Teneobio and Five Key Therapeutics. Wang also aided strike scientific collaborations for Amgen’s most cancers pipeline, such as 1 with biotech BeiGene.
Wang’s occupation also features time used as a mergers and acquisitions marketing consultant at Deloitte.
“We are pleased to welcome Haibo as senior vice president of enterprise growth at Harpoon,” Julie Eastland, president and CEO of Harpoon Therapeutics, reported in a assertion. “Haibo’s extensive experience and strategic acumen will play a pivotal job in driving our business enterprise progress and forging impactful partnerships.”
Harpoon, which focuses on immunotherapies for most cancers, is now building T mobile engagers that trigger a patient’s T cells to target specified antigen-expressing cells, using its platform, Tri-precise T cell Activating Construct (TriTAC).
In March 2022, the pharma made the decision to discontinue its after-primary applicant for prostate most cancers and invest in other therapies.
Its pipeline at the moment consists of 3 immunotherapies presently in Stage 1 trials – HPN328 (DLL3) for compact cell lung cancer, HPN217 (BCMA) for multiple myeloma, and HPN536 for ovarian cancer and other stable tumors. Harpoon is also executing preclinical work on 4 other therapies, together with a person in gastrointestinal cancers.
In April, Harpoon presented preclinical benefits on equally HPN217 and HPN328, saying the latter had “potential for long-phrase anti-tumor immunity and sturdy responses in individuals.”
“With our Stage 1 trial ongoing and further more reports